Granted Patent
B2
US 12,576,103 · App. 17/802,711 · Granted Mar 17, 2026
Heparin and N-acetylcysteine for the treatment of lung injury
Assignee:
Atossa Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are compositions and methods for treatment or prevention of a respiratory viral infection. A composition of the present disclosure comprises one or more of heparin, or N-acetylcysteine. A composition for treatment or prevention of a respiratory viral infection may be administered by inhalation in intervals. Administration of a composition may treat or prevent a viral infection.
Claims (17)
1 . A method of treating a lung injury in a subject in need thereof, the method comprising:
administering by inhalation a composition comprising a therapeutically effective amount of a heparin and N-acetylcysteine to the subject, thereby treating the lung injury in the subject and showing a physiological improvement, shorter duration of ventilator support, reduced mortality, or any combination thereof.
2 . The method of claim 1 , wherein the method inhibits a pulmonary inflammation in the subject.
3 . The method of claim 1 , wherein the method improves a lung function in the subject, as measured by a daily oxygenation index.
4 . The method of claim 1 , wherein the heparin has an average molecular weight of at least 4 kDa and not more than 5 kDa.
5 . The method of claim 1 , wherein the heparin is enoxaparin.
6 . The method of claim 1 , wherein the heparin is administered at a daily dose of at least 10,000 IU and not more than 400,000 IU.
7 . The method of claim 1 , wherein the N-acetylcysteine is administered at a daily dose of at least 1 g and not more than 30 g.
8 . The method of claim 1 , wherein the N-acetylcysteine is administered at a daily dose of at least 400 mg and not more than 700 mg.
9 . The method of claim 1 , wherein the heparin and the N-acetylcysteine are nebulized.
10 . The method of claim 1 , wherein the method comprises continuously administering the heparin and N-acetylcysteine, over a period of at least 8 hours.
11 . The method of claim 1 , wherein the method comprises administering the heparin and N-acetylcysteine, at least three times per day.
12 . The method of claim 1 , wherein the N-acetylcysteine is formulated as an aqueous N-acetylcysteine solution further comprising disodium edetate.
13 . The method of claim 12 , wherein the aqueous N-acetylcysteine solution has about 200 mg per mL N-acetylcysteine.
14 . The method of claim 12 , wherein the aqueous N-acetylcysteine solution has not less than 0.1 mg per mL and not more than 5 mg per mL disodium edetate.
15 . The method of claim 1 , wherein the heparin is formulated as an aqueous heparin solution.
16 . The method of claim 15 , wherein the aqueous heparin solution comprises about 100 mg per mL heparin.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 7, 2023
From: QUAY, STEVEN C.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 062668/0446 →
Continuity (7)
Provisional Application
63038092
· Jun 11, 2020
Provisional Application
63026674
· May 18, 2020
Provisional Application
63011287
· Apr 16, 2020
Provisional Application
63006050
· Apr 6, 2020
Provisional Application
63001344
· Mar 29, 2020
Provisional Application
62993644
· Mar 23, 2020
References Cited (86)
US 4511069A
· Kalat
· 1985
[cited by applicant]
US 5681811A
· Ekwuribe
· 1997
[cited by applicant]
US 20060229276A1
· Hook et al.
· 2006
[cited by applicant]
US 20100143312A1
· Hariri
· 2010
[cited by examiner]
US 20140288267A1
· Tripp et al.
· 2014
[cited by applicant]
CN 107653228A
· 2018
[cited by applicant]
WO WO2005020885A2
· 2005
[cited by applicant]
WO WO2016120787A1
· 2016
[cited by applicant]
Kummarapurugu et al. Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis. J. Biol. Chem. (2018) 293(32) 12480-12490. (Year: 2018).
[cited by examiner]
Elsharnouby et al. Heparin/N-acetylcysteine: An adjuvant in the management of burn inhalation injury: A study of different doses. Journal of Critical Care 29 (2014) 182.e1-182.e4. (Year: 2014).
[cited by examiner]
Andersen K., et al., “The Proximal Origin of SARS-CoV-2,” Nature medicine 26.4 (2020): 450-452.
[cited by applicant]
Ashraf U., et al., “Nebulized Heparin and N-Acetylcysteine for Smoke Inhalational Injury,” Clinical Case Report, Medicine, vol. 97, No. 19, e0638, 2018, pp. 1-4.
[cited by applicant]
Barbucci R., et al., “Swelling Behavior of Carboxymethylcellulose Hydrogels in Relation to Cross-Linking, pH, and Charge Density,” Macromolecules, vol. 33(20), pp. 7475-7480. (2000).
[cited by applicant]
Battle., et al., “Soluble Angiotensin-Converting Enzyme 2: a Potential Approach for Coronavirus Infection Therapy?,” Clinical Science, vol. 134(5), Mar. 13, 2020, pp. 543-545.
[cited by applicant]
Becker G.I., et al., “Highly Potent Inhibitors of Proprotein Convertase Furin as Potential Drugs for Treatment of Infectious Diseases,” Journal of Biological Chemistry, vol. 287(26), Jun. 22, 2012, pp. 21992-22003.
[cited by applicant]
Belouzard S., et al., “Activation of the SARS Coronavirus Spike Protein via Sequential Proteolytic Cleavage at Two Distinct Sites,” Proceedings of the National Academy of Sciences 106.14 (2009): 5871-5876.
[cited by applicant]
Bendstrup K.E., et al., “Effect of inhaled heparin on lung function and coagulation in healthy volunteers,” European Respiratory Journal 19.4 (2002): 606-610.
[cited by applicant]
Bendstrup K.E., et al., “Inhaled Heparin is Effective in Exacerbations of Asthma,” Respiratory Medicine, Feb. 2000, vol. 94, No. 2, pp. 174-175.
[cited by applicant]
Borsig L., “Heparin as in Inhibitor of Cancer Progression,” Progress in Molecular Biology and Translational Science, vol. 93, 2010, pp. 335-349.
[cited by applicant]
Cao Y., et al., “Comparative Genetic Analysis of the Novel Coronavirus (2019-nCoV/SARS-CoV-2) Receptor ACE2 in Different Populations,” Cell Discovery, 2020, vol. 6(11), 4 pages.
[cited by applicant]
Cazzola M., et al., “Influence of N-acetylcysteine on Chronic Bronchitis or COPD Exacerbations: a Meta-Analysis,” European Respiratory Society, 2015, vol. 24, pp. 451-461.
[cited by applicant]
Chen C., et al., “Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues,” Proceedings of the National Academy of Sciences 117.16 (2020): 8890-8899.
[cited by applicant]
Choy K., et al., “Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro,” Antiviral research 178 (2020): 104786, 5 pages.
[cited by applicant]
Coutard B., et al., “The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade,” Antiviral research 176 (2020): 104742, 6 pages.
[cited by applicant]
Desai M.H., et al., “Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy,” Journal of Burn Care & Rehabilitation, May 1998, …
[cited by applicant]
Feng F., et al., “Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis,” Experimental and therapeutic medicine 18.1 (2019): 802-816.
[cited by applicant]
Gautret P., et al., “Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-randomized Clinical Trial,” International journal of antimicrobial agents (2020): 105949, 24 pages.
[cited by applicant]
Haan C.A.M.D., et al., “Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded off against Heparan Sulfate Binding upon Cell Culture Adaptation,” Journal of Virology, vol. 82(12), pp. 6078-6083, (2…
[cited by applicant]
Haan C.A.M.D., et al., “Murine Coronavirus with an Extended Host Range Uses Heparan Sulfate as an Entry Receptor,” Journal of Virology, Nov. 2005, vol. 79(22), pp. 14451-14456.
[cited by applicant]
Haeger S.M., et al., “Heparan Sulfate in the Developing, Healthy, and Injured Lung,” American Journal of Respiratory Cell and Molecular Biology, 2016, vol. 55(1) pp. 5-11.
[cited by applicant]
Hamahata A., et al., “Gamma-Tocopherol Nebulization by a Lipid Aerosolization Device Improves Pulmonary Function in Sheep with Burn and Smoke Inhalation Injury,” Free Radical Biology & Medicine, Aug. 15, 2009, vol. 45(4…
[cited by applicant]
Hardes K., et al., “Novel Furin Inhibitors with Potent Anti-infectious Activity,” ChemMedChem, 2015, vol. 10(7), pp. 1218-1231.
[cited by applicant]
Huang X., et al., “Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme,” Journal of Virolog…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/023256, mailed May 26, 2021, 10 pages.
[cited by applicant]
Izaguirre G., “The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases,” Viruses, 2011, vol. 11(9): 837, 19 pages.
[cited by applicant]
Jia H.P., et al., “Ectodomain Shedding of Angiotensin Converting Enzyme 2 in Human Airway Epithelia,” American Journal of Physiology Lung Cellular and Molecular Physiology, 2009, vol. 297, pp. 1.84-1.96.
[cited by applicant]
Jin Z., et al., “Structure of M pro from SARS-CoV-2 and Discovery of its Inhibitors,” Nature (2020), 24 pages.
[cited by applicant]
Juschten J., et al., “Nebulized anticoagulants in lung injury in critically ill patients—an updated systematic review of preclinical and clinical studies,” Annals of Translational Medicine, Nov. 2017, vol. 5(22):444, 12…
[cited by applicant]
Kahler Z.P., et al., “Cost of Treating Venous Thromboembolism with Heparin and Warfarin Versus Home Treatment With Rivaroxaban,” Academic Emergency Medicine, 2015, vol. 22(7), pp. 796-802.
[cited by applicant]
Kent L.H., t al., “Physico-chemical studies of poly-d-glutamic acid from Bacillus anthracis grown in vitro,” Microbiological Research Establishment, Jun. 6, 1957, vol. 250, pp. 1-43.
[cited by applicant]
Lang J., et al., “Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans,” PLoS One, 2011, 11 pages.
[cited by applicant]
Latorre R., et al., “Voltage-Dependent Conductance Induced by aLamethicin-phospholipid Conjugates in Lipid Bilayers,” Biophysical journal 36.3 (1981), 803-809.
[cited by applicant]
Lee M “Heparin inhibits activation of latent transforming growth factor-β1,” Pharmacology 92.5-6 (2013): 238-244.
[cited by applicant]
Li H., et al., “The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery,” European Journal of Pharmaceutical Sciences, 2010, vol. 40, pp. 56-61.
[cited by applicant]
Lin L., et al., “Hypothesis for Potential Pathogenesis of SARS-CoV-2 Infection—a Review of Immune Changes in Patients with Viral Pneumonia,” Emerging Microbes & Infections, 9.1 (2020), 727-732.
[cited by applicant]
Liu H., et al., “Lessons Learned from the Contamination of Heparin,” Natural Product Reports, Mar. 2009, vol. 26(3), 22 pages.
[cited by applicant]
Lukassen S., et al., “SARS-CoV-2 Receptor ACE 2 and TMPRSS 2 are Primarily Expressed in Bronchial Transient Secretory Cells,” The EMBO journal 39.10 (2020): e105114, 15 pages.
[cited by applicant]
Ma S.N., et al., “The Anti-Cancer Properties of Heparin and its Derivatives: A Review and Prospect,” Cell Adhesion & Migration, vol. 14, No. 1, 2020, pp. 118-128.
[cited by applicant]
Manning M.C., et al., “Stability of Protein Pharmaceuticals,” Pharmaceutical Research, 1989, vol. 6 (11), pp. 903-918.
[cited by applicant]
McIntire A.M., et al., “Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study),” Journal of Burn Care & Research 38.1 (2017): 45-52.
[cited by applicant]
Milewska A., et al., “Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells,” Journal of Virology, 2014, vol. 88(22), pp. 13221-13230.
[cited by applicant]
Molina J.M., et al., “No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection,” Med Mal Infect 50.384 (2020), p…
[cited by applicant]
Mu S., et al., “Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury,” Respiratory research 19.1 (2018): 220, 15 pages.
[cited by applicant]
Mycroft-West C., et al., “The 2019 Coronavirus (SARS-CoV-2) Surface Protein (Spike) S1 Receptor Binding Domain Undergoes Conformational Change upon Heparin Binding,” BioRxiv (2020), 9 pages.
[cited by applicant]
Paborji M., et al., “Chemical and Physical Stability of Chimeric L6, a Mouse-Human Monoclonal Antibody,” Pharmaceutical Research, May 1994, vol. 11(5), pp. 764-771.
[cited by applicant]
Peng M., et al., “Luteolin Restricts Dengue Virus Replication Through Inhibition of the Proprotein Convertase Furin,” 2017, vol. 143, 48 pages.
[cited by applicant]
Pramanick et al. “Excipient Selection In Parenteral Formulation Development” Mar. 2013, Pharma Times 45(3):65-77.
[cited by applicant]
Quay S.C., et al., “Conformational studies of aqueous melittin: thermodynamic parameters of the monomer-tetramer self-association reaction,” Biochemistry 22.3 (1983): 695-700.
[cited by applicant]
Quay S.C., et al., “Molecular mechanisms of alamethicin channel gating,” Biophysical journal 37.1 (1982): 154-156.
[cited by applicant]
Racaniello V “Furin Cleavage Site in the SARS-CoV-2 Coronavirus Glycoprotein,” Virology blog, 2020, 27 pages.
[cited by applicant]
Riley M., et al., “Position Statement on Heparin Safety Concerns,” The Journal of Pediatric Pharmacology and Therapeutics, 2016, vol. 21(6), pp. 530-532.
[cited by applicant]
Rose L.M., et al., “Development of the first inhaled antibiotic for the treatment of cystic fibrosis,” Science Translational Medicine, Dec. 22, 2010; 2(63): 63mr4, 5 pages.
[cited by applicant]
Sainz-Serp D., et al., “Purification of Natural Anionic Polymers,” Minerva Biotecnologica, 2005, vol. 17(4), 1 page.
[cited by applicant]
Schoeman D., et al., “Coronavirus Envelope Protein: Current Knowledge,” Virology journal 16.1 (2019): 69. 22 pages.
[cited by applicant]
Seaman M., “Sodium polyphosphate enhances the antimicrobial activities of whole and fractionated peanut skin extract against food spoilage yeasts in a model juice system,” Graduate Theses and Dissertations, 2013, 90 pag…
[cited by applicant]
Sheahan T.P., et al., “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses,” Science translational medicine 9.396 (2017), 17 pages.
[cited by applicant]
Shen W.F., et al. Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody, Elife 7 (2018): e38970, 24 pages.
[cited by applicant]
Sidleychem, “Properties of Sodium Carboxymethyl Cellulose,” Retrieved from Internet URL: https://celluloseether.com/properties-of-cmc-carboxymethylcellulose/, Retrieved on Jul. 15, 2020, 2 pages.
[cited by applicant]
Stehli D., et al., “Collapsed State of Polyglutamic Acid Results in Amyloid Spherulite Formation,” Intrinsically Disordered Proteins, 2015, vol. 3(1). 12 pages.
[cited by applicant]
Sturrock E.D., et al., “Assignment of Free and Disulfide-Bonded Cysteine Residues in Testis Angiotensin-Converting Enzyme: Functional Implications,” Biochemistry, 1996, vol. 35(29), pp. 9560-9566.
[cited by applicant]
Thuma J.B., et al., “Choline and NMDG directly reduce outward currents: reduced outward current when these substances replace Na+ is alone not evidence of Na+-activated K+ currents,” Journal of Neurophysiology, vol. 120…
[cited by applicant]
Ullian., et al., “N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells,” Journal of the American Society of Nephrology 16.8 (2005): 2346-2353.
[cited by applicant]
Ulus I.H., et al., “Choline as an Agonist: Determination of its Agonistic Potency on cholinergic Receptors,” Biochemical Pharmacology, 1988, vol. 37(14), pp. 2747-2755.
[cited by applicant]
Verdia-Baguena C., et al., “Coronavirus E protein Forms ion Channels with Functionally and Structurally-Involved Membrane Lipids,” Virology, vol. 432, 2012, pp. 485-494.
[cited by applicant]
Vicenzi E., et al., “Coronaviridae and SARS-associated Coronavirus Strain HSR1,” Emerging Infectious Diseases, 2004, vol. 10(3), pp. 413-418.
[cited by applicant]
Wang M., et al., “Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro,” Cell Research, vol. 30: 269-271, Feb. 4, 2020, Retrieved on May 12, 2021, Retrieved from the…
[cited by applicant]
Yahata T., et al., “Modulation of Airway Responsiveness by Anionic and Cationic Polyelectrolyte Substances,” European Journal of Pharmacology, 2002, vol. 434(1-2):71-9.
[cited by applicant]
Yan S., et al., “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2,” Science, vol. 367(6485), Mar. 27, 2020, pp. 1444-1448.
[cited by applicant]
Yu Y., et al., “Adjuvant Therapy with Heparin in Patients with Lung Cancer without Indication for Anticoagulants: A Systematic Review of the Literature with Meta-Analysis,” Journal of Cancer Research and Therapeutics, v…
[cited by applicant]
Zaretzky F.R., et al., “Sulfated Polyanions Block Chlamydia Trachomatis Infection of Cervix-Derived Human Epithelia,” Infection and Immunity, Sep. 1995, vol. 63(9), pp. 3520-3526.
[cited by applicant]
Zielinski M., et al., “Is inhaled heparin a viable therapeutic option in inhalation injury?,” Advances in respiratory medicine 87.3 (2019): 184-188.
[cited by applicant]
Lee Y-J., et al., “Suppression of Human Prostate Cancer PC-3 Cell Growth by N-Acetylcysteine Involves Over-Expression of Cyr61,” Toxicology in Vitro, Elsevier Science, vol. 25, No. 1, Feb. 1, 2011, pp. 199-205.
[cited by applicant]
Page C., “Heparin and Related Drugs: Beyond Anticoagulant Activity,” ISRN Pharmacology, vol. 2013, Jan. 1, 2013, 14 pages.
[cited by applicant]
Yip L.Y., et al., “Safety and Potential Anticoagulant Effects of Nebulised Heparin in Burns Patients with Inhalational Injury at Singapore General Hospital Burns Centre,” Burns, Jul. 4, 2011, vol. 37, No. 7, XP028297499…
[cited by applicant]